The shifting landscape of state-level healthcare policy has recently been personified by a dramatic regulatory experiment in Tennessee, where traditional prescription barriers have been dismantled for the antiparasitic drug ivermectin. James Maitland, a distinguished voice in healthcare policy and technology integration, has spent years examining how legislative shifts can disrupt the standard of care and the safety of medical distribution. His work often bridges the gap between traditional clinical oversight and the emerging, sometimes volatile, world of tech-driven health misinformation and non-traditional pharmacy practices. In this conversation, we explore the implications of Tennessee’s 2022 law, the rise of “ideological” medicine, and the profound challenges state health authorities face when trying to track medications that have moved from the exam room to the roadside billboard.
How do collaborative pharmacy practice agreements change the typical patient-provider relationship, and what specific safeguards are bypassed when drugs like ivermectin are sold via blanket prescriptions?
The typical patient-provider relationship is built on a foundation of individual diagnosis, where a doctor evaluates a specific human being’s medical history and current symptoms before tailoring a treatment plan. Under Tennessee’s 2022 law, this personal clinical engagement is largely replaced by a “collaborative pharmacy practice agreement,” which essentially acts as a pre-written, nonspecific prescription that covers any customer who walks through the door. We see figures like Denise Sibley, a physician who has inked as many as 40 of these agreements with pharmacies across the state, creating a system where the traditional gatekeeper role of the doctor is significantly diluted. While the law technically requires pharmacists to ask questions about a customer’s existing medications and conditions, the reality is that the physician often only receives a record of the sale after the fact, rather than conducting a prior assessment. This shift bypasses the critical diagnostic step, allowing the drug to be marketed for everything from diabetes to cancer despite a lack of clinical evidence. By turning a prescription drug into a near-over-the-counter product, we lose the safeguard of individualized risk-benefit analysis, which is why we’ve seen people traveling from Canada and Europe to exploit these loosened Tennessee regulations.
What are the primary health risks associated with the high-potency versions of this medication being sold in Tennessee, and how are these risks manifesting in real-world data?
The safety profile of ivermectin changes drastically when the dosage is manipulated, and in Tennessee, compounding pharmacies are offering pills that are sometimes 10, 20, or even 21 times the potency of a standard FDA-approved tablet. While ivermectin is generally safe in standard doses for parasitic diseases, the FDA has warned that large doses can be dangerous, a fact reinforced by the rise in calls to the Tennessee Poison Center. In 2025 alone, the center received more than 60 calls for possible ivermectin poisoning, the highest number since the height of the pandemic in 2021. Patients are reporting distressing symptoms like blurred vision, difficulty walking, vomiting, and significant neurological problems as they experiment with “bucketloads” of the drug. Some protocols circulating in these pharmacies recommend taking 1.5 to five times the normal parasitic dose for days or even weeks at a time, turning a once-a-year treatment into a chronic, high-risk regimen. This is no longer just about a dewormer; it is a clinical experiment occurring in real-time, often among vulnerable populations like cancer patients who are paying up to $19 per pill for unproven hope.
Why has ivermectin evolved from a Nobel Prize-winning antiparasitic into what some experts call an “ideological flag,” and what role does misinformation play in its current popularity?
The transformation of ivermectin into a symbol of resistance against the medical establishment is a fascinating, if troubling, case study in the power of political identity over scientific data. For many, it has become a central pillar of the “Make America Healthy Again” movement, championed by figures like Robert F. Kennedy Jr., and promoted by influencers who position it as a “wonder drug” suppressed by “big medicine.” This ideological capture was supercharged by media moments like a 2025 Joe Rogan podcast episode where Mel Gibson claimed the drug helped cure stage 4 cancer, leading to a measurable spike in prescribing rates despite zero evidence for such claims. When people view a drug as a panacea for everything from “long-haul vax symptoms” to the flu and RSV, they stop looking for data and start looking for “testimonies,” as we’ve heard from local pharmacists. It creates a “captured audience” that is susceptible to profit-driven motives and a deep-seated distrust of the biomedical community. The drug is no longer just a medication; it is a tool for creating a parallel medical reality where “God-given” intuition and internet rumors override the rigorous scrutiny of clinical trials.
How significant is the breakdown in regulatory oversight in Tennessee, and what does it mean for the state’s ability to protect its citizens?
The regulatory situation in Tennessee is a massive blind spot that should concern anyone interested in public health surveillance. Although pharmacies are legally required to notify the Department of Health when they enter into these collaborative agreements, the state is failing to track the market effectively. In a recent investigation, the health agency could only produce records for 12 pharmacies, yet independent researchers identified at least 13 other locations selling ivermectin without individual prescriptions that the state had no record of. This means over half of the identifiable market is operating in an “unlit path” where the government does not know who is selling the drug or in what quantities. Because much of this happens through compounding pharmacies that create customized, non-FDA-approved medications paid for in cash, federal and insurance data sources are also largely blind to the volume of sales. When the state’s own medical boards say their “hands are tied” by the legislature, and the Department of Health refuses to answer questions about its regulation of the drug, you have a perfect storm where safety becomes secondary to political will.
What are the legal and ethical implications of the immunity clauses written into the 2022 ivermectin law, especially regarding pharmacist liability and patient safety?
The inclusion of immunity from lawsuits or professional sanctions in the Tennessee law is one of its most controversial features, as it removes the traditional legal deterrents that prevent medical malpractice. Members of the state’s medical boards have openly expressed shock that such a law passed without their input, worrying that a cash-based market with no liability would inevitably attract “shady characters” looking to profit from vulnerable patients. Ethically, this creates a situation where a pharmacist can sell a high-potency drug for a condition like Parkinson’s disease—for which there is no evidence of efficacy—without fearing the professional consequences that usually govern the dispensing of medicine. If a patient experiences neurological damage or poisoning, their path to legal recourse is significantly obstructed, which shifts all the risk onto the consumer while the profit stays with the provider. It essentially incentivizes “quack science” by rewarding those who follow the “narrative” rather than the science, a dynamic that Dr. John Mafi from UCLA rightly described as a return to 19th-century medical practices. We are seeing pharmacies like Roman Pharmacy and Compound Rx aggressively advertising on billboards and websites, knowing that the legal guardrails that typically maintain the standard of care have been dismantled.
As other states look to Tennessee as a model for similar legislation, what are the broader consequences for the American healthcare system and the future of evidence-based medicine?
Tennessee was the harbinger of a national trend, with more than two dozen states considering or debating “look-alike” bills that would make ivermectin available without a doctor’s visit. We’ve already seen Arkansas, Idaho, Louisiana, and Texas enact similar laws in 2025, suggesting that the politicization of medication is becoming a standard legislative tool across a large portion of the country. This trend threatens to undermine the very foundation of evidence-based medicine by suggesting that legislative bodies, rather than scientific research, should determine the “choice” of treatments available to the public. In states like Oklahoma, there is fierce pushback from clinicians who worry about children being given these drugs, yet the momentum remains strong among those who view it as a matter of personal liberty rather than clinical safety. If we continue down this path, we risk creating a bifurcated healthcare system where one half of the country relies on peer-reviewed data and the other half relies on dropdown menus of favorite right-wing influencers to determine their medical care. This fragmentation makes it nearly impossible to manage public health crises or ensure that patients are receiving proven treatments for life-threatening illnesses like cancer.
What is your forecast for the future of these decentralized pharmacy practices and the legislative attempts to regulate them?
I suspect we are entering a period of significant friction where the clinical reality of increased poisonings and failed treatments will eventually clash with the political fervor surrounding these laws. In Tennessee, we already see a hint of this with State Senator Richard Briggs, the lone Republican who voted against the bill, planning to introduce legislation in 2027 to rein in the misleading advertising and dangerous market that has emerged. However, the “hard sell” he expects from anti-vaccine groups suggests that the road back to science-based policy will be long and arduous. We will likely see more medical boards, like Tennessee’s Board of Medical Examiners, trying to distance themselves from the controversy by scrubbing mentions of ivermectin from public reprimands, even as they struggle to manage the fallout from doctors who have abandoned standard protocols. The real test will come when the financial and human costs of these high-potency, unmonitored drug sales become too high to ignore, forcing a reckoning between the “choice” championed by advocates and the duty of care that the state is supposed to uphold. Until then, we will continue to see a marketplace where 21-times potency pills are sold for $19 a pop to a public that has been taught to view the facts as a mere “inconvenience.”
